Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: A disease-oriented approach

Journal of Radiation Research

Volumn 57, Issue , 2016, Pages i58-i68

  Ricardi, Umberto ^a   Badellino, Serena ^a   Filippi, Andrea Riccardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

oligometastases; radiosurgery; radiotherapy; stereotactic ablative radiotherapy; stereotactic body radiotherapy

Indexed keywords

BIOLOGICAL ORGANS; DECISION MAKING; DISEASE CONTROL; DISEASES; ONCOLOGY; TUMORS;

ABLATIVE THERAPY; CANCER PATIENTS; CLINICAL APPLICATION; INTERMEDIATE STATE; OLIGOMETASTASIS; RADIOSURGERY; SOLID TUMORS; STEREOTACTIC ABLATIVE RADIOTHERAPIES; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC BODY RADIOTHERAPY;

RADIOTHERAPY;

EID: 84988597505     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rrw006     Document Type: Conference Paper

References (72)

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
2. Hellman S. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34.
3. Lo SS, Fakiris AJ, Teh BS, et al. Stereotactic body radiation therapy for oligometastases Expert Rev Anticancer Ther 2009;9:621-35.
4. Schultz DB, Filippi AR, Thariat J, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 2014;9:1426-33.
5. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiation therapy for oligometastases. Lancet Oncol 2013;14:e28-37.
6. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013;31:1-8.
7. Salama JK, Chmura AJ. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol 2014;41:790-7.
8. Niibe I, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010;40:107-11.
9. Senan S, Guckenberger M, Ricardi U. Stage I NSCLC and oligometastatic disease. In Ball D, Scagliotti GV (eds). The IASLC Multidisciplinary Approach to Thoracic Oncology. Aurora, CO: International Association for the Study of Lung Cancer, 2014.
10. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state: separate truth from wishful thinking. Nat Rev Clin Oncol 2014; 11:549-57.
11. Ksienski D, Woods R, Speers C, et al. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 2010;17:3085-93.
12. Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 2012;14: 333-41.
13. De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 2012;7:1547-55.
14. Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non-small cell lung cancer patients. Ann Oncol 2014;25:1954-9.
15. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014;15:346-55.
16. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation. Lancet Oncol 2009;10:1037-44.
17. Flannery TW, Suntharalingam M, Regine WF, et al. Long-term survival in patients with synchronous, solitary brain metastases from non-small cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008;72:19-23.
18. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th edn. Chicago: Springer, 2009.
19. De Rose F, Cozzi L, Navarria P, et al. Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients. Clin Oncol 2016;28:13-20.
20. Tanvetyanon T, Robinson LA, Schell MJ, et al. Ouctomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008;26:1142-7.
21. Holy R., Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-51.
22. Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys 2012;82:919-23.
23. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol 2012;51:618-23.
24. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxelin pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57.
25. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
26. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: 3327-34.
27. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
28. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-14.
29. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR-tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346-51.
30. Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic radiotherapy combined with erlotinib for patients with limited but progressive disease metastatic non-small cell lung cancer. J Clin Oncol 2014;32:3824-30.
31. Palma DA, Videtic GM. Oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2015;93:223-6.
32. Blackwell KI, Burnstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012;30:2585-92.
33. Greenberg PA, Hortobagyi GN, Simth TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
34. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2007;112:650-8.
35. Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009;115:601-8.
36. Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2011;83:878-86.
37. Lewis S, Porceddu S, Nakamura N, et al. (2 February 2015) Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of 1000 radiation oncologists. Am J Clin Oncol (epub ahead of print).
38. Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012;151:710-16.
39. Yoon SS, Tanabe KK. Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 1999;4: 197-208.
40. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-6.
41. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
42. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900-9.
43. Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004;78:238-44.
44. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007;84:324-38.
45. Kanemitsu Y, Kato T, Hirai T, et al. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004;91:112-20.
46. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19:1206-13.
47. Siperstein A, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007;246:559-67.
48. Chua TC, Thornbury K, Saxena A, et al. Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer 2010;116:2106-14.
49. Schlijper R, Grutters J, Houben R, et al. What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? Canc Treat Rev 2014; 40:60-7.
50. Alongi F, Arcangeli S, Filippi AR, et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012;17:1100-7.
51. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-8.
52. Filippi AR, Badellino S, Guarneri A, et al. Outcomes of single fraction stereotactic ablative radiotherapy in lung metastases. Tech Canc Res Treat 2014;13:37-45.
53. Lee M, Kim J, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27:1585-91.
54. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86:336-42.
55. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology 2009;76:212-9.
56. Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011;101:255-9.
57. Filippi AR, Badellino S, Ceccarelli M, et al. Stereotactic Ablative Radiation Therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. Int J Radiat Oncol Biol Phys 2015;91:524-9.
58. Qiu H, Katz AW, Chowdhry H, et al. (11 August 2015) Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol (epub ahead of print).
59. Comito T, Cozzi L, Clerici E, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014;14:619.
60. Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015;67:852-63.
61. Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011;97:49-55.
62. Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases from prostate cancer. Urol Oncol 2011;31:455-61.
63. Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012;2:215.
64. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic imageguided stereotactic radiotherapy for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:889-97.
65. Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013;52:1622-8.
66. Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014;9:135.
67. Ost P, Jereczeck-Fossa BA, Van As N, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naïve recurrence: a multi-institutional analysis. Eur Urol 2016;69:9-12.
68. Lo SS, Sloan AE, Machtay M. Stereotactic radiosurgery for more than four brain metastases. Lancet Oncol 2014;15:362-3.
69. Lussier YA, Xing HR, Salama KK, et al. MicroRNA expression characterizes oligometastases. PloS One 2011;6:e28650.
70. Lussier YA, Khodarev NN, Regan K, et al. Oligo-and polymetastatic progression in lung metastases patients is associated with specific microRNAs. PloS One 2012;7:e50141.
71. Solanki AA, Weichselbaum RR, Appelbaum D, et al. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol 2012;7:216.
72. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.